ClinicalTrials.gg
CompletedNCT06155721RTCSSCUpdated Jun 11, 2026Results posted

Development and Evaluation of Virtual Reality Experiences for Cognitive Stimulation at the Sociosanitary Center El Carme

An interventional study of Virtual Reality Cognitive Stimulation Program in Cognitive Dysfunction and Mild Cognitive Impairment, sponsored by Badalona Serveis Assistencials. Completed at 1 site in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Badalona Serveis Assistencials · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Cognitive Dysfunction with a site in Spain — 44 open to participants now, 61 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.

Enrollment
102nd of 127
45 · median 100
Started
2023
with 13 others
No phase
91 of 162
27 open now
Registered
108th of 162
by date

Among the 162 studies in Cognitive Dysfunction with a site in Spain, this one is the 102nd largest by enrollment of the 127 interventional ones that give a count, is one of 14 that started in 2023, is one of 91 with no phase, and was the 108th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

44 of the 162 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Cognitive Dysfunction with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a virtual reality (VR)-based program designed for cognitive stimulation in individuals attending the conventional cognitive rehabilitation program at the Day Hospital of CSSC (Centro Sociosanitario El Carme) in Badalona, Spain. The trial will specifically assess VR's impact on declarative memory and executive functions through interactive exercises, as well as attention and episodic memory through VR video stimuli.

The main questions it aims to answer are:

  • Will patients with mild cognitive impairment find the VR program enjoyable and easy to use?
  • Can VR interventions help improve patients' cognitive functions, specifically attention and memory?
  • Do healthcare professionals find VR a practical tool for cognitive stimulation in their clinical practice?

Participants will undergo a series of 8 sessions, scheduled twice a week to coincide with the conventional rehabilitation appointments. The VR equipment used will be Oculus Quest 2 headsets, offering an immersive experience with hand-tracking technology that simplifies interactions, particularly beneficial for those with mild cognitive impairment (MCI). During the study, participants will:

  • Engage with a VR-based cognitive stimulation program.
  • Undergo assessments of the participants´ cognitive functions before and after the intervention.
  • Provide feedback on the participants´ experience with the VR program.

Researchers will analyze the data to see if:

  • The VR program leads to noticeable improvements in the cognitive abilities of participants.
  • The program is well-received and deemed beneficial by both patients and healthcare professionals.
Read the detailed description

Background:

Cognitive impairment affects a significant portion of the aging population, leading to challenges in daily functioning and a reduced quality of life. Traditional cognitive rehabilitation techniques have shown benefits, but patient engagement and adherence remain challenging. Innovations such as virtual reality (VR) offer new avenues for cognitive stimulation, potentially enhancing patient involvement and treatment outcomes.

Study Design:

This clinical trial aims to evaluate the acceptability and efficacy of a VR-based cognitive stimulation program among patients with mild to moderate cognitive impairment at Centro Sociosanitario El Carme in Badalona. It will employ a pretest-posttest design to assess cognitive changes, utilizing standardized cognitive scales and gathering qualitative feedback on user experience.

Objectives:

Primary Objective: To assess the acceptability of the VR-based cognitive stimulation program among patients with mild to moderate cognitive impairment.

Secondary Objectives:

To evaluate whether the VR interventions are perceived as engaging and motivating by the patients, which would suggest positive adherence to the cognitive stimulation program.

To measure changes in cognitive performance, particularly in attention and memory, pre- and post-intervention, to determine the effectiveness of the program.

To understand healthcare professionals' perceptions of the applicability of VR interventions in clinical practice for cognitive stimulation.

To identify potential improvements for the implementation of the VR program based on patient and healthcare staff feedback.

To gather data that could be useful for the development of future VR experiences aimed at patients with cognitive impairments.

Methodology:

Participants will be recruited from the Centro Sociosanitario El Carme and will undergo an initial assessment to establish a cognitive baseline. The participants will then engage in a series of VR sessions designed to provide cognitive stimulation. The program will focus on exercises to enhance attention and memory, incorporating interactive elements to maintain engagement. After completing the sessions, participants will be re-assessed using the same cognitive scales.

Feedback on the VR experience will be collected through structured interviews and questionnaires to gauge acceptability, perceived usefulness, and motivation. Healthcare professionals involved in the administration of the VR program will also be interviewed to understand their views on the integration of VR into therapeutic practices.

Expected Outcomes:

It is hypothesized that the VR program will be well-received by patients, evidenced by high rates of program completion and positive subjective feedback. Post-intervention improvements in cognitive scale scores are expected, indicating the potential efficacy of VR-based stimulation. Insights from healthcare professionals are anticipated to highlight the practicality of VR in clinical settings and suggest improvements for future applications.

Relevance:

The findings from this trial could support the adoption of VR technologies in cognitive rehabilitation, offering a novel, scalable, and potentially more effective approach to managing cognitive impairments. The study may also contribute to the evidence base required for integrating technological innovations into standard healthcare practice.

Conclusion:

By exploring the intersection of VR technology and cognitive rehabilitation, this study seeks to advance the understanding of innovative treatments for cognitive impairments and foster improved patient outcomes through enhanced engagement and stimulation.

03

Conditions studied

  • Cognitive Dysfunction
  • Mild Cognitive Impairment

Keywords

  • Cognitive Stimulation
  • Virtual Reality
  • Mild Cognitive Impairment
  • Cognitive Rehabilitation
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be classified as having mild cognitive impairment with a (MMSE) score greater than 23.
  • Participants must be currently attending cognitive rehabilitation sessions at the Day Hospital of the Centro Sociosanitario El Carme (CSSC).
  • Participants must be able to give or, in the case of incapacity, consent must be obtained from their legal representative.

Exclusion criteria

Exclusion Criteria:

  • Patients with a severe or unstable illness that could interfere with participation in the study.
  • Patients with serious psychiatric disorders, such as psychotic disorders, delusions, or hallucinations that may be exacerbated by the use of virtual reality.
  • Patients with severe visual limitations that would prevent the use of virtual reality.
  • Presence of ocular diseases causing blurred vision that cannot be corrected with contact lenses or glasses.
  • Presence of auditory pathologies that cause a significant decrease in hearing without hearing aids.
  • High sensitivity to motion sickness.
  • Subjects with epilepsy.
  • Patients who are unable or unwilling to give .

Withdrawal Criteria

The emergence of health problems that could interfere with the continuity of participation in the study, or the withdrawal of consent by the participant.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Virtual Reality Cognitive Stimulation Program

    Participants with MCI undergo 8 VR sessions, using Oculus Quest 2 headsets for immersive cognitive exercises. Activities include a Supermarket Shopping Task for memory, a Payment Task for cognitive flexibility, and a Recipe Sequencing Task for problem-solving. Additionally, 360-degree videos with visuo-verbal stimulation are used to engage attention and episodic memory, monitored by therapists. The investigators employ Oculus Quest 2 VR headsets with hand tracking technology to provide a seamless and immersive experience, especially beneficial for participants with Mild Cognitive Impairment (MCI).

    Device: Virtual Reality Cognitive Stimulation Program

Interventions

  • DeviceVirtual Reality Cognitive Stimulation Program

    Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.

06

What researchers measure

Primary outcomes

  1. Usability of VR Exercises as Measured by an Adapted 8-Item System Usability Scale (SUS)

    Adapted 8-Item System Usability Scale (SUS): Score Range: 0 to 100 points Interpretation: Higher scores indicate better usability.

    Time frame: immediately post-intervention, within 30 minutes after the last intervention session- 8th session (day 8)

  2. Comfort of VR Headset as Measured by an 8-Item SUS:

    Adapted 8-Item VR Headset Comfort Rating: Score Range: 0 to 100 points Interpretation: Lower scores indicate better comfort (as most items measure discomfort).

    Time frame: immediately post-intervention, within 30 minutes after the 8th session (day 8)

Secondary outcomes

  1. Professional´s Usability of VR Exercises as Measured by an Adapted 8-Item SUS:

    Scale Title: Professional System Usability Scale (SUS) Score Range: 0 to 100 points Interpretation: Higher scores indicate a professional's perception of better system usability for patient care.

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

  2. VR Headset Comfort Rating for Professionals as Measured by an Adapted 3-Item SUS:

    Scale Title: Professional System Usability Scale (SUS) Score Range: 0 to 100 points Interpretation: Higher scores indicate better comfort and ease of use for the VR headset; lower scores indicate greater discomfort and difficulty with use. This rating is based on a professional assessment of the VR headset's weight, design, and control scheme's impact on patient comfort during use.

    Time frame: immediately post-intervention, within 30 minutes after the 8th session (day 8)

  3. Global Cognition as Measured by the Mini-Mental State Examination (MMSE)

    MMSE is a 30-point questionnaire evaluating orientation, attention, recall, language, and visual construction Score Range: 0 to 30 points. Higher scores means better global cognition function

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

  4. Global Cognition as Measured by the Montreal Cognitive Assessment (MoCA)

    MoCA is a 30-point screening tool for global cognitive function, assessing memory, attention, language, visuospatial skills, and executive function. Score Range: 0 to 30 points \- Higher scores means better global cognition function

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

  5. Short-Term Memory as Measured by the Digit Span Test (DST Forward Span)

    Forward Digit Span measures verbal short-term memory. Score Range: 0 to 9 points \- Higher scores indicate better short-term verbal memory.

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

  6. Working Memory as Measured by the Digit Span Test (DST Backward Span)

    Backward Digit Span assesses working memory and mental manipulation. Score Range: 0 to 9 points. Higher scores indicate better working memory.

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

  7. Visuospatial Attention as Measured by the Trail Making Test Part A (TMT-A)

    TMT-A measures visual attention and processing speed. The outcome is time to completion measured in seconds, typically ranging from several seconds to several minutes. Lower times (faster completion) indicate better visuospatial attention.

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

  8. Executive Function as Measured by the Trail Making Test Part B (TMT-B)

    TMTB: Trial Making Test B. Score Range: Time to complete the test measured in seconds, typically ranging from several seconds to several minutes. Lower times (faster completion) indicate better alternating attention.

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

  9. Processing Speed as Measured by the Symbol Digit Modalities Test (SDMT)

    SDMT: Symbol Digit Modalities Test. The Symbol Digit Modalities Test (SDMT) measures processing speed, attention, and visual-motor coordination. During the test, participants are required to match abstract symbols with corresponding numbers using a key. The total raw score is calculated as the number of correct symbol-digit pairs completed within a 90-second interval. There is no fixed maximum score, as it varies based on individual performance. Higher scores indicate better processing speed and cognitive performance.

    Time frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

Other outcomes

  1. Demographics Variables

    Age: numeric

    Time frame: Baseline

  2. Demographics Variables

    Gender: 0=female, 1=male, 3=others

    Time frame: Baseline

07

Results

Posted Mar 25, 2025

Participant flow

The study included two separately recruited pilot groups of patients with mild cognitive impairment (MCI) participating in cognitive stimulation sessions at our outpatient unit. Group 1 (n = 25) was enrolled in Period 1 (Mondays and Wednesdays), and Group 2 (n = 20) in Period 2 (Tuesdays and Thursdays), each after applying inclusion criteria. Each group was independent, with no participant overlap. So the number of participants in Period 2 does not correspond to the number completing Period 1.

Pilot Group 1
Participant flow — Pilot Group 1
MilestoneVirtual Reality Cognitive Stimulation Program
Started25
Completed23
Not completed2
Pilot Group 2
Participant flow — Pilot Group 2
MilestoneVirtual Reality Cognitive Stimulation Program
Started20
Completed17
Not completed3

Outcome measures

PrimaryUsability of VR Exercises as Measured by an Adapted 8-Item System Usability Scale (SUS)

Adapted 8-Item System Usability Scale (SUS): Score Range: 0 to 100 points Interpretation: Higher scores indicate better usability.

Time frame:
immediately post-intervention, within 30 minutes after the last intervention session- 8th session (day 8)
Reported as:
Mean · score on a scale from 0-100
Usability of VR Exercises as Measured by an Adapted 8-Item System Usability Scale (SUS)
score on a scale from 0-100Virtual Reality Cognitive Stimulation Program
Usability of VR Exercises as Measured by an Adapted 8-Item System Usability Scale (SUS)81.9 ± 14.9
PrimaryComfort of VR Headset as Measured by an 8-Item SUS:

Adapted 8-Item VR Headset Comfort Rating: Score Range: 0 to 100 points Interpretation: Lower scores indicate better comfort (as most items measure discomfort).

Time frame:
immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Mean · score on a scale from 0-100
Comfort of VR Headset as Measured by an 8-Item SUS:
score on a scale from 0-100Virtual Reality Cognitive Stimulation Program
Comfort of VR Headset as Measured by an 8-Item SUS:86.5 ± 13.3
SecondaryProfessional´s Usability of VR Exercises as Measured by an Adapted 8-Item SUS:

Scale Title: Professional System Usability Scale (SUS) Score Range: 0 to 100 points Interpretation: Higher scores indicate a professional's perception of better system usability for patient care.

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Mean · score on a scale from 0-100
Professional´s Usability of VR Exercises as Measured by an Adapted 8-Item SUS:
score on a scale from 0-100Virtual Reality Cognitive Stimulation Program
Professional´s Usability of VR Exercises as Measured by an Adapted 8-Item SUS:85.2 ± 10.9
SecondaryVR Headset Comfort Rating for Professionals as Measured by an Adapted 3-Item SUS:

Scale Title: Professional System Usability Scale (SUS) Score Range: 0 to 100 points Interpretation: Higher scores indicate better comfort and ease of use for the VR headset; lower scores indicate greater discomfort and difficulty with use. This rating is based on a professional assessment of the VR headset's weight, design, and control scheme's impact on patient comfort during use.

Time frame:
immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Mean · score on a scale from 0-100
VR Headset Comfort Rating for Professionals as Measured by an Adapted 3-Item SUS:
score on a scale from 0-100Virtual Reality Cognitive Stimulation Program
VR Headset Comfort Rating for Professionals as Measured by an Adapted 3-Item SUS:60.4 ± 22.9
SecondaryGlobal Cognition as Measured by the Mini-Mental State Examination (MMSE)

MMSE is a 30-point questionnaire evaluating orientation, attention, recall, language, and visual construction Score Range: 0 to 30 points. Higher scores means better global cognition function

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Median · score on a scale
Global Cognition as Measured by the Mini-Mental State Examination (MMSE)
score on a scaleBaseline - Virtual Reality Cognitive Stimulation ProgramPost-Intervention - Virtual Reality Cognitive Stimulation Program
Global Cognition as Measured by the Mini-Mental State Examination (MMSE)26 ± 2.1226.5 ± 2.3
SecondaryGlobal Cognition as Measured by the Montreal Cognitive Assessment (MoCA)

MoCA is a 30-point screening tool for global cognitive function, assessing memory, attention, language, visuospatial skills, and executive function. Score Range: 0 to 30 points \- Higher scores means better global cognition function

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Median · score on a scale
Global Cognition as Measured by the Montreal Cognitive Assessment (MoCA)
score on a scaleBaseline - Virtual Reality Cognitive Stimulation ProgramPost-Intervention - Virtual Reality Cognitive Stimulation Program
Global Cognition as Measured by the Montreal Cognitive Assessment (MoCA)19 ± 4.1920 ± 4.4
SecondaryShort-Term Memory as Measured by the Digit Span Test (DST Forward Span)

Forward Digit Span measures verbal short-term memory. Score Range: 0 to 9 points \- Higher scores indicate better short-term verbal memory.

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Median · score on a scale
Short-Term Memory as Measured by the Digit Span Test (DST Forward Span)
score on a scaleBaseline - Virtual Reality Cognitive Stimulation ProgramPost-Intervention - Virtual Reality Cognitive Stimulation Program
Short-Term Memory as Measured by the Digit Span Test (DST Forward Span)4.5 ± 1.14.5 ± 0.96
SecondaryWorking Memory as Measured by the Digit Span Test (DST Backward Span)

Backward Digit Span assesses working memory and mental manipulation. Score Range: 0 to 9 points. Higher scores indicate better working memory.

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Median · score on a scale
Working Memory as Measured by the Digit Span Test (DST Backward Span)
score on a scaleBaseline - Virtual Reality Cognitive Stimulation ProgramPost-Intervention - Virtual Reality Cognitive Stimulation Program
Working Memory as Measured by the Digit Span Test (DST Backward Span)3 ± 0.973 ± 0.77
SecondaryVisuospatial Attention as Measured by the Trail Making Test Part A (TMT-A)

TMT-A measures visual attention and processing speed. The outcome is time to completion measured in seconds, typically ranging from several seconds to several minutes. Lower times (faster completion) indicate better visuospatial attention.

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Median · seconds
Visuospatial Attention as Measured by the Trail Making Test Part A (TMT-A)
secondsBaseline - Virtual Reality Cognitive Stimulation ProgramPost-Intervention - Virtual Reality Cognitive Stimulation Program
Visuospatial Attention as Measured by the Trail Making Test Part A (TMT-A)70.5 ± 50.465.5 ± 38.3
SecondaryExecutive Function as Measured by the Trail Making Test Part B (TMT-B)

TMTB: Trial Making Test B. Score Range: Time to complete the test measured in seconds, typically ranging from several seconds to several minutes. Lower times (faster completion) indicate better alternating attention.

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Median · seconds
Executive Function as Measured by the Trail Making Test Part B (TMT-B)
secondsBaseline - Virtual Reality Cognitive Stimulation ProgramPost-Intervention - Virtual Reality Cognitive Stimulation Program
Executive Function as Measured by the Trail Making Test Part B (TMT-B)195.5 ± 421205 ± 426
SecondaryProcessing Speed as Measured by the Symbol Digit Modalities Test (SDMT)

SDMT: Symbol Digit Modalities Test. The Symbol Digit Modalities Test (SDMT) measures processing speed, attention, and visual-motor coordination. During the test, participants are required to match abstract symbols with corresponding numbers using a key. The total raw score is calculated as the number of correct symbol-digit pairs completed within a 90-second interval. There is no fixed maximum score, as it varies based on individual performance. Higher scores indicate better processing speed and cognitive performance.

Time frame:
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Reported as:
Median · Number of correct corresponding pairs
Processing Speed as Measured by the Symbol Digit Modalities Test (SDMT)
Number of correct corresponding pairsBaseline - Virtual Reality Cognitive Stimulation ProgramPost-Intervention - Virtual Reality Cognitive Stimulation Program
Processing Speed as Measured by the Symbol Digit Modalities Test (SDMT)17 ± 9.818.5 ± 9.5
Other pre-specifiedDemographics Variables

Age: numeric

Time frame:
Baseline
Reported as:
Median · years
Demographics Variables
yearsVirtual Reality Cognitive Stimulation Program
Demographics Variables75.5 ± 6.19
Other pre-specifiedDemographics Variables

Gender: 0=female, 1=male, 3=others

Time frame:
Baseline
Reported as:
Count of participants · Participants
Demographics Variables
ParticipantsVirtual Reality Cognitive Stimulation Program
Male17
Female23

Adverse events

Collected over Adverse event data were collected over a 3-month period during the pilot study.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Virtual Reality Cognitive Stimulation Program0/45 (0%)0/45 (0%)2/45 (4.4%)
Most frequent other events
Most frequent other events
EventVirtual Reality Cognitive Stimulation Program
CybersicknessEar and labyrinth disorders2/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)Virtual Reality Cognitive Stimulation Program
Median75 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)Virtual Reality Cognitive Stimulation Program
Female27
Male18
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Virtual Reality Cognitive Stimulation Program
Hispanic or Latino44
Not Hispanic or Latino1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Virtual Reality Cognitive Stimulation Program
Spain45
Global Cognition State as Measured by the MMSE
Global Cognition State as Measured by the MMSE(units on a score 0-30)Virtual Reality Cognitive Stimulation Program
Median25.98 ± 2.02
Global Cognition State as Measured by the MoCA
Global Cognition State as Measured by the MoCA(units on a score 0-30)Virtual Reality Cognitive Stimulation Program
Median17.98 ± 4.35
Short Term Verbal Memory as Measured by DST (Forward Span)
Short Term Verbal Memory as Measured by DST (Forward Span)(units on a score 0-9)Virtual Reality Cognitive Stimulation Program
Median4 ± 1.07
Working Memory as Measure by the DST (Backward Span)
Working Memory as Measure by the DST (Backward Span)(units on a score 0-9)Virtual Reality Cognitive Stimulation Program
Median3 ± 0.93

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Centro Socio Sanitario El Carmen
    Badalona, Barcelona 08917, Spain
09

References and documents

Publications

  • Journal of Medical Extended RealityVol. 2, No. 1 Published Online: 21 March 2025 Virtual Reality in Cognitive Rehabilitation: A Pilot Study on Usability and Preliminary Clinical Outcomes in Seniors with Mild Cognitive Impairment Authors: Jose Ferrer Costa, Maria Jose Ciudad, Maribel González Abad, and José Luis Rodríguez García
  • Perra A, Riccardo CL, De Lorenzo V, De Marco E, Di Natale L, Kurotschka PK, Preti A, Carta MG. Fully Immersive Virtual Reality-Based Cognitive Remediation for Adults with Psychosocial Disabilities: A Systematic Scoping Review of Methods Intervention Gaps and Meta-Analysis of Published Effectiveness Studies. Int J Environ Res Public Health. 2023 Jan 14;20(2):1527. doi: 10.3390/ijerph20021527. PubMed 36674283 ↗
  • Zuschnegg J, Schoberer D, Haussl A, Herzog SA, Russegger S, Ploder K, Fellner M, Hofmarcher-Holzhacker MM, Roller-Wirnsberger R, Paletta L, Koini M, Schussler S. Effectiveness of computer-based interventions for community-dwelling people with cognitive decline: a systematic review with meta-analyses. BMC Geriatr. 2023 Apr 12;23(1):229. doi: 10.1186/s12877-023-03941-y. PubMed 37041494 ↗
  • Bauer ACM, Andringa G. The Potential of Immersive Virtual Reality for Cognitive Training in Elderly. Gerontology. 2020;66(6):614-623. doi: 10.1159/000509830. Epub 2020 Sep 9. PubMed 32906122 ↗
  • Liao YY, Chen IH, Lin YJ, Chen Y, Hsu WC. Effects of Virtual Reality-Based Physical and Cognitive Training on Executive Function and Dual-Task Gait Performance in Older Adults With Mild Cognitive Impairment: A Randomized Control Trial. Front Aging Neurosci. 2019 Jul 16;11:162. doi: 10.3389/fnagi.2019.00162. eCollection 2019. PubMed 31379553 ↗
  • Gomez-Caceres B, Cano-Lopez I, Alino M, Puig-Perez S. Effectiveness of virtual reality-based neuropsychological interventions in improving cognitive functioning in patients with mild cognitive impairment: A systematic review and meta-analysis. Clin Neuropsychol. 2023 Oct;37(7):1337-1370. doi: 10.1080/13854046.2022.2148283. Epub 2022 Nov 23. PubMed 36416175 ↗
  • Munoz J, Mehrabi S, Li Y, Basharat A, Middleton LE, Cao S, Barnett-Cowan M, Boger J. Immersive Virtual Reality Exergames for Persons Living With Dementia: User-Centered Design Study as a Multistakeholder Team During the COVID-19 Pandemic. JMIR Serious Games. 2022 Jan 19;10(1):e29987. doi: 10.2196/29987. PubMed 35044320 ↗
  • Papaioannou T, Voinescu A, Petrini K, Stanton Fraser D. Efficacy and Moderators of Virtual Reality for Cognitive Training in People with Dementia and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2022;88(4):1341-1370. doi: 10.3233/JAD-210672. PubMed 35811514 ↗
  • Qiu R, Gu Y, Xie C, Wang Y, Sheng Y, Zhu J, Yue Y, Cao J. Virtual reality-based targeted cognitive training program for Chinese older adults: A feasibility study. Geriatr Nurs. 2022 Sep-Oct;47:35-41. doi: 10.1016/j.gerinurse.2022.06.007. Epub 2022 Jul 12. PubMed 35839753 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Not applicable; individual participant data will not be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Feb 2024, 3 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 3 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Dec 4, 2023
StartActual
Oct 30, 2023
Primary completionActual
Feb 27, 2024
CompletionActual
Mar 27, 2024
Results first posted
Mar 25, 2025
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06155721
Lead sponsor
Badalona Serveis Assistencials
Collaborators
Public Health Agency of Barcelona, Reality Telling SL
Responsible party
Jose Ferrer Costa (Principal Investigator, Badalona Serveis Assistencials) — Principal investigator
First posted
Dec 4, 2023
Start date
Oct 30, 2023
Primary completion
Feb 27, 2024
Completion
Mar 27, 2024
Results posted
Mar 25, 2025
Last update
Jun 11, 2026

Study contacts

Jose Ferrer Costa, MD
principal investigator · Medical Researcher and Project Manager

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion